Characterization of nonrapid virologic response patients infected with HCV genotype 1 who may relapse after standard therapy with peginterferon plus ribavirin

Approximately 50% of patients with hepatitis C virus (HCV) genotype 1 treated with peginterferon alfa-2a/ribavirin discontinue treatment early or experience a suboptimal response despite 48 weeks of therapy. The objective of this analysis was to develop a model to identify nonrapid virologic respons...

Descripción completa

Detalles Bibliográficos
Autores principales: Reau, N, Hamzeh, F M, Lentz, E, Zhou, X, Jensen, D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2012
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3489051/
https://www.ncbi.nlm.nih.gov/pubmed/22239499
http://dx.doi.org/10.1111/j.1365-2893.2010.01422.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3489051/
https://www.ncbi.nlm.nih.gov/pubmed/22239499
http://dx.doi.org/10.1111/j.1365-2893.2010.01422.x

Ejemplares similares